Cleared Traditional

OPTILINE, CARLO BELLINI, EXPLOREFLEX, STRATFORD & TITINIFLEX (K943236) - FDA 510(k) Clearance

Class I Ophthalmic device.

K943236 · Optiline Imports and Trade, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1994
Decision
27d
Days
Class 1
Risk

K943236 is an FDA 510(k) clearance for the OPTILINE, CARLO BELLINI, EXPLOREFLEX, STRATFORD & TITINIFLEX. Classified as Frame, Spectacle (product code HQZ), Class I - General Controls.

Submitted by Optiline Imports and Trade, Inc. (Woodland Hills, US). The FDA issued a Cleared decision on August 2, 1994 after a review of 27 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.5842 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Optiline Imports and Trade, Inc. devices

Submission Details

510(k) Number K943236 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 06, 1994
Decision Date August 02, 1994
Days to Decision 27 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
83d faster than avg
Panel avg: 110d · This submission: 27d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HQZ Frame, Spectacle
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 886.5842
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.